SCHEMBL876243

SCHEMBL876243

NC1CCC(=O)N(C(=O)OCc2ccccc2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
CYP2C19 P33261 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
CTRB1 P17538 1/20 0.47
P2RX4 Q99571 2/20 0.47
P2RX1 P51575 1/20 0.46
P2RX3 P56373 1/20 0.46
HTR2C P28335 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
ELANE P08246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274967 0.81 P2RX4 (0.58) SMN1; SMN2CYP2C19NPC1RAB9ACTRB1
SCHEMBL4475242 0.81 ADRA2A (0.37) SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1
SCHEMBL8526862 0.79 P2RX4 (0.55) SMN1; SMN2CYP2C19NPC1RAB9ACTRB1
SCHEMBL1903246 0.79 TSHR (0.45) MEN1KMT2A
SCHEMBL6632615 0.78 SMN1; SMN2 (0.54) SMN1; SMN2CYP2C19NPC1RAB9AHTR2C
SCHEMBL7977283 0.78 SMN1; SMN2 (0.54) SMN1; SMN2CYP2C19NPC1RAB9AHTR2C
Hydrochloric Acid SCHEMBL6632612 0.77 SMN1; SMN2 (0.53) SMN1; SMN2CYP2C19NPC1RAB9AHTR2C
Hydrochloric Acid SCHEMBL6632617 0.77 SMN1; SMN2 (0.53) SMN1; SMN2CYP2C19NPC1RAB9AHTR2C
SCHEMBL9009580 0.77 P2RX4 (0.50) SMN1; SMN2CYP2C19NPC1RAB9ACTRB1
SCHEMBL24379310 0.75 ALDH1A1 (0.39) L3MBTL1MEN1KMT2APSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
CN-105440014-A Preparation method of lenalidomide HANGZHOU HEZE PHARMACEUTICAL TECH CO LTD 2016-03-30 CN disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
EP-2438053-B1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) 2013-09-11 EP disclosed
EP-2438053-A1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-04-11 EP disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed
WO-2010139266-A1 METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS SMN1; SMN2 3098/4885CYP2C19 61/4885NPC1 2049/4885
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof DHPS, QDPR, FDPS SMN1; SMN2 2783/4885CYP2C19 118/4885NPC1 1917/4885
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS SMN1; SMN2 2783/4885CYP2C19 118/4885NPC1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.